Nebenwirkungen · Abseamed
Abseamed 1 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3 000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4 000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6 000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7 000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8 000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9 000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10 000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20 000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30 000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40 000 IU/1 mL solution for injection in a pre-filled syringe · Abschnitt 4.8 · PDF-Seite 17
HOS-117341 · Präparat HOS-094577
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T17:02:00Z · SHA-256 3e1b737ee1405883d6ada05e33aebffc5aada961e1e56f0ea2f9f2b70e597f63 · Passage 591ce3aa6d6555db7032d0551da929e990b92080da2928085827a75c666ec353 · Zeichen 7238–7552 im Abschnitt